The link between Treg and the efficacy evaluation of tumor response to different treatments is found in anthracycline-based NAC, anti-HER2 NAC, but the relationship is still unknown in other treatments, which is a potential research field for us to manipulate Treg to reach the highest efficacy of these treatment strategies. The gene discussed is ERBB2; the disease is neoplasm.